Abstract
Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.
Keywords: Prostate cancer, bladder cancer, testicular cancer, positron emission tomography, F-18-fluorodeoxyglucose
Current Medicinal Chemistry
Title: Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers
Volume: 17 Issue: 23
Author(s): A. Zouhair, M. Ozsahin, M. Schaffer, S. Albrecht, F. Camus, P. Jichlinski, R.-O. Mirimanoff, A. Bischof Delaloye, J.-Y. Meuwly and J.O. Prior
Affiliation:
Keywords: Prostate cancer, bladder cancer, testicular cancer, positron emission tomography, F-18-fluorodeoxyglucose
Abstract: Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.
Export Options
About this article
Cite this article as:
Zouhair A., Ozsahin M., Schaffer M., Albrecht S., Camus F., Jichlinski P., Mirimanoff R.-O., Bischof Delaloye A., Meuwly J.-Y. and Prior J.O., Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers, Current Medicinal Chemistry 2010; 17 (23) . https://dx.doi.org/10.2174/092986710791556014
DOI https://dx.doi.org/10.2174/092986710791556014 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Simplified Receptor Based Pharmacophore Approach to Retrieve Potent PTP-LAR Inhibitors Using Apoenzyme
Current Computer-Aided Drug Design Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy Surgical Staging for Cervical Cancer
Current Women`s Health Reviews Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Gene Delivery for Cancer Therapy
Current Drug Delivery Current Status of Primary Cytoreductive Surgery for the Treatment of Advanced Epithelial Ovarian Cancer
Current Cancer Therapy Reviews Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets The Effect of Drugs on the Labeling of Blood Elements with Technetium-99m
Current Pharmaceutical Design New Hope for Intervertebral Disc Degeneration: Bone Marrow Mesenchymal Stem Cells and Exosomes Derived from Bone Marrow Mesenchymal Stem Cell Transplantation
Current Gene Therapy Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Synthesis of Asymmetric 1-Thiocarbamoyl Pyrazoles as Potent Anti- Colon Cancer, Antioxidant and Anti-Inflammatory Agent
Anti-Cancer Agents in Medicinal Chemistry Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design